Rating 5 out of 5. Alexion (ALXN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Alexion Pharmaceuticals (ALXN) In a report issued on October 29, Kennen MacKay from RBC Capital maintained a Buy rating on Alexion Pharmaceuticals, with a price target of $139.00. The company has an excellent track record, delivering an earnings beat in the trailing four quarters by 11.65%, on average. We're building on our fundamental understanding of complement biology and advancing on our core therapeutic areas of hematology . Found insideAlexion. Pharmaceuticals. Inc. SPOOR'S. S&P Recommendation 1 Price 12-Mo. Target Price Investment Style Summary This ... Alexion Pharmaceuticals develops novel ... S&P Quality Ranking BlDlCIIBIPlA-IAIPI Relative Strength Rank WEAK ... C-RATED STOCKS are those stocks our Big Data multi-factor models score as probable to have negligible return for the month. How Style Scores Work with the Zacks Rank. Alexion Pharmaceuticals Inc., case number 2020-1069, in the Court of Chancery of the State of Delaware. Found inside – Page 91... Country Company ratio Country Hindustan Unilever 46.6 India Alexion Pharma. ... Rank. Note: the table shows companies from the FT Global 500 with the ... A vastly improved search engine helps you find the latest on companies, business leaders, and news more easily. BioMarin Pharmaceutical , Corcept Therapeutics and Genmab are among the top 5 highly rated stocks in the group. (5 days ago) Alexion Pharmaceuticals, Inc. stock has gained 72.33% over the last 12 months, and the average rating from Wall Street analysts is a Hold. Pharmaceutical. The relocation package was great I was . Alexion Pharmaceuticals (ALXN) came out with quarterly earnings of $2.96 per share, beating the Zacks Consensus Estimate of $2.50 per share. Found inside – Page 18... Amerika Serikat 34.10% 58.15% 22 Alexion Pharmaceuticals Amerika Serikat ... https://www.forbes.com/innovative-companies/list/#tab:rank DISRUPSI: SIAP! The market expects Alexion Pharmaceuticals (ALXN) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2021. Any forward looking estimates presented by Quantalytics may prove to be incorrect and not be realized. Keep me posted on new Alexion Pharmaceuticals Rankings. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Q3 2015 Earnings Conference Call October 29, 2015 10:00 AM ET Executives. Healthcare. Number of Employees. Given Alexionâs purpose-driven mission, much of our day-to-day operations contribute to our position as a leading corporate citizen. Despite growing its EBITDA per share by nearly 100% since 2018, the company’s stock has increased less than 10% over that period. Its products include ultomiris, soliris, strensiq and kanuma. 3. This compares to earnings of $3.22 per share a year ago. Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life . Market capitalization of Alexion Pharmaceuticals (ALXN) Market cap: $40.33 Billion As of September 2021 Alexion Pharmaceuticals has a market cap of $40.33 Billion.This makes Alexion Pharmaceuticals the world's 492th most valuable company by market cap according to our data. Found insideIndustry Code Sales Rank Profits Rank (U.S. $ thousands) (U.S. $ thousands) ... 19 931,000 18 ALEXION PHARMACEUTICALS 325412 1,064 165 -108,750 190 ALFACELL ... read our 2019 Corporate Social Responsibility Report, Meeting Needs in Rare Disease Takes More than Medicine, Alexionâs CEO Speaks to the Companyâs Corporate Social Responsibility Progress, Alexion Receives Boston Cares 2020 Corporate Partner of the Year Award. The analysts price targets range from a high of . Next, [...], Despite an expected dip in profit, analysts are generally optimistic about Alexion Pharmaceuticals as it prepares to reports its first-quarter earnings on Thursday, April 23, 2015. Last Update: Jul 28, 2021. . Source: Alexion Pharmaceuticals, Inc. News Provided by Acquire Media One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum [...], At Holdings Channel, we have reviewed 4,049 13F filings for the 06/30/2015 reporting period, and looked at the various S&P 500 components held by each of these reporting hedge funds and other 13F filers. World's Most Innovative Companies. The company primarily operates in the US, Europe and Asia Pacific. For each component, we totaled the number of shares across across all of these funds. The consensus earnings per share estimate is $1.18 per share.The consensus estimate has decreased from $1.19 over the past month. Alexion, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $1.44. Upon completion, Alexion shareholders will own 15% of the . The Q-Factor Score represents an expectation for how a stock will perform in a given month. Please, enter valid e-mail address. Phone. 17. But that’s not new. The company's shares closed last Wednesday at $123.35, close to its 52-week high of $128.57. Found inside – Page 167... sponsored by Alexion Pharmaceuticals, was a prospective, double-blind, ... to placebo measured by worst-rank analysis of covariance (ANCOVA) analysis. Found insideIndustry Code Sales Rank Profits Rank (U.S. $ thousands) (U.S. ... -5,963 66 ALCON INC 325412 4,896,600 21 1,348,100 16 ALEXION PHARMACEUTICALS 325412 1,558 ... If you're interested in career opportunities with AstraZeneca, click here.. Alexion Pharmaceuticals. Get prepared with the key expectations. See other locations. Company Rank in USA in 2021 is 235. Since the launch of our CSR function in late 2017, strategy in late 2018, and inaugural CSR Report in March of this year, Alexion has moved from the 37th percentile to the 1st percentile in the Sustainalytics ranking. Found insideThis logic applies particularly well to the pharmaceutical sector. ... Alexion Pharmaceuticals managed to rank 314th among world's largest corporations in ... Below is a chart of Alexion Pharmaceuticals Inc. versus VF Corp. plotting their respective size rank within the S&P 500 over time (ALXN plotted in blue; VFC plotted in green): Any data, information, or opinions in Quantalytics in any form attributed to a third party represent Quantalytics’ interpretation of the data, information, or opinions provided by that third party either publicly or through a subscription service, and such use and interpretation have not been reviewed by the third party. Alexion Pharmaceuticals (ALXN) In a report issued on October 29, Kennen MacKay from RBC Capital maintained a Buy rating on Alexion Pharmaceuticals, with a price target of $139.00. ALXN has a Momentum Style Score of A, and shares are up 3.4% over the past four weeks.One analysts revised their earnings estimate higher in the last 60 days for fiscal 2021, while the Zacks . Found inside – Page 35cumulative index 1989-2008 : includes references to all listings in twenty editions of Business rankings annual ... 3806 ) 1995 Ed . ( 3716 ) Alexian Brothers Health System 2002 Ed . ( 4062 ) Alexion Pharmaceuticals , Inc. 2003 Ed ... Quantalytics does not make any representations as to their accuracy or completeness. Address. Alexion Pharmaceuticals (ALXN) came out with quarterly earnings of $3.24 per share, beating the Zacks Consensus Estimate of $2.59 per share. Alexion Pharmaceuticals (ALXN) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2021. Our indicative theme of Out Of Favor Healthcare Stocks is down by about -9% year-to-date versus the S&P 500 which is up by about 7.9% over the same period. Found inside – Page 954Two biotechnology stocks , Alexion Pharmaceuticals , Inc. ( ALXN ) and Osiris Therapeutics , Inc. ( OSIR ) have fallen ... As noted in our update , however , we have raised our ranking on the shares to Buy / Hold on the premise that the ... Found inside – Page 372Rank Pharma Company Revenue (million $) Biopharma Company Revenue (million $) . ... Laboratories 16,486 Alexion.Pharmae 387 Source: From. Contract. Pharma. Nearly 90% of Alexionâs shares are held by institutions, including its two biggest shareholders, Vanguard Group and BlackRock. Rankings are based on government and proprietary data on salaries, company financial health, and employee . All Rights Reserved. Alexion Pharmaceuticals, Inc. Media Stephanie Fagan, 203-271-8223 Senior Vice President, Corporate Communications or Investors Elena Ridloff, CFA, 203-699-7722 Vice President, Investor Relations. My husband Manuel Gomez is currently employed with Alexion, we love the benefits, They have a great maternity leave for men and for women, for men they provide a month of paid absence and for woman it is 3 months which I think is amazing considering other companies only give 3 weeks. Among its products are a treatment for a rare blood disease as well as the only approved complement inhibitor to treat a rare central nervous system disorder. ALXN has a higher market value than 92.92% of US stocks; more precisely, its current market capitalization is $39,661,900,824. Michigan Economic Development Corporation Insights, Alexion Pharmaceuticals: Good Growth But Out Of Favor, Stocks This Week: Short Mattel And Alexion Pharmaceuticals, Stocks This Week: Mondelez, IDEXX Labs And Alexion Pharmaceuticals, Why Alexion Pharmaceuticals Is Overvalued, Alexion Pharmaceuticals is Now Oversold (ALXN), Oversold Conditions For Alexion Pharmaceuticals (ALXN), Alexion Pharmaceuticals Becomes Oversold (ALXN), Funds Added To Alexion Pharmaceuticals Positions, Relative Strength Alert For Alexion Pharmaceuticals, Profit Expected to Dip for Alexion Pharmaceuticals, Anticipated Earnings Increase for Alexion Pharmaceuticals. *InvestorsObserver's* proprietary ranking system, gives ALXN stock a score of 82 out of a possible 100. Zippia's Best Places to Work lists provide unbiased, data-based evaluations of companies. Alexion Pharmaceuticals (ALXN) came out with quarterly earnings of $3.52 per share, beating the Zacks Consensus Estimate of $3.08 per share. Technology. Found inside – Page 163For example, with only one product for a very rare disease, Alexion Pharmaceuticals managed to rank 314th among the world's largest corporations in terms of ... The market expects Alexion Pharmaceuticals (ALXN) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2020. Alexion shares fell 1% to 101.35 Thursday afternoon. Found inside – Page 12Book Flow Price 2007 Rept Name of issue Rank Fiscal Mean High Low Ests . EPS Mean High Low Ests . Mean High Low Ests ... 1 317 40.14 5.07 105.85 42 5/09 Alexion Pharmaceuticals с Dc Q1 01.06 00.88 01.16 8 vd4.15 d3.96 d3.36 4.36 8 d2.58 ... Employee Count as on Date. Found inside – Page 22006 RANK FIRM 5700 91.7 +1,242 -59 NM 40 -60 2800 91.3 +217 -1 -303 9 -9 3800 91.1 -2 59 NM 555 +12 2600 90.7 +71 40 ... +12 11 +2,978 18 +147 261 REX STORES CORP . , Dayton , Ohio 262 ALEXION PHARMACEUTICALS INC . , Cheshire , Conn . After almost 30 years as an independent company, Alexion was acquired by AstraZeneca in June, 2021. Found inside – Page 60Here's a look at the 14 S&P stocks with the highest valuations: Rank/Company (ticker) P-E ratio 1. Amazon (AMZN) 942.2 2. ... Alexion Pharma (ALXN) 156.7 8. All investments and investment recommendations entail risks. These stocks are the best “SHORTS” for investors. Some better-ranked stocks in the healthcare sector include Emergent Biosolutions Inc. EBS, Castle Biosciences, Inc. CSTL and AVEO Pharmaceuticals . Analysts are expecting earnings of [...], Wall Street is high on Alexion Pharmaceuticals, expecting it to report earnings that are up 46% from a year ago when it reports its fourth-quarter earnings on Thursday, January 29, 2015. Alexion Pharmaceuticals earns the No. Get prepared with the key expectations. While these stocks are ranked ATTRACTIVE, we believe the best buys for long positions are TOP BUYS which are A-rated stocks. AstraZeneca is splashing out $39 billion to buy Alexion in a cash-and-stock deal, the British pharma revealed Saturday. AstraZeneca PLC (LSE:AZN) entered into a definitive agreement to acquire Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN) for $40.2 billion on December 12, 2020. While Alexion Pharmaceuticals is down the least... Alexion Pharmaceuticals stock hasn’t moved much this year. Boston-based Alexion Pharmaceuticals develops medicine for rare diseases. It is headquartered in Cheshire, Connecticut, and employed 2,924 people as on December 31, 2015. Such data, information, or opinions are not an offer to sell or to buy, or a solicitation to buy or sell any securities. Though it pales in comparison to last year's jumbo pharma deals - Bristol-Myers Squibb acquired Celgene for $74 billion, and . Found inside – Page 75... 13,959 Profits Rank 78 117 79 69 14 198 81 91 26 48 128 20 23 196 109 1,000 178 4,700 53 45 14 91 64 ADVANCED MAGNETICS INC AEOLUS PHARMACEUTICALS AETERNA ZENTARIS INC AKORN INC ALCON INC ALEXION PHARMACEUTICALS ALFACELL CORPORATION ... Alexion Pharmaceuticals, Inc. should also file a new Labor Condition Application (LCA) for an H1B Visa petition if the foreign worker changes work location within Alexion Pharmaceuticals, Inc., because the prevailing wage will change. Q.ai, LLC is a wholly owned subsidiary of Quantalytics Holdings, LLC (“Quantalytics”). Found inside – Page 82The Fortune Global 500, annual ranking of corporations worldwide as measured ... 4 Incyte United States 46.0699371% 70.8% 5 Alexion Pharmaceuticals United ... The P/E ratio of Alexion Pharmaceuticals is 59.64, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 18.92. 16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alexion Pharmaceuticals in the last twelve months. Alexion Pharmaceuticals is ranked #33 on the Best Pharmaceutical Companies to Work For in America list. Here are a trio of stocks that are projected to move over the next few weeks. These figures are adjusted for non-recurring items. The consensus estimate is $1.17 per share, up from earnings of 80 cents per share a year ago.Analysts are projecting [...], Why AstraZeneca Wants To Buy Alexion Pharmaceuticals, Stocks This Week: Sell Short Alexion Pharmaceuticals And Mattel, Acadia, Novocure & Alexion Stocks Are Out Of Favor, But Promising. Late last week, AstraZeneca said that it would acquire Alexion Pharmaceuticals - a company best known for its Soliris and Ultomiris drugs - in a cash and stock deal valued at about $39 billion. Revenue also increased, from 23% to 27%. That rank is chiefly influenced by a short-term technical score of 90. Listed Company. ALEXION PHARMACEUTICALS INC. United States of America (US) OpenCorporation rating: 9.46 on 100 Ranking 2018: 1719 on 589 companies Primary and secondary NACE classification: • Manufacture of pharmaceutical preparations (2120) • Research and experimental development on biotechnology (7211) Found insideInnovativeness rankings published by Forbes magazine took a completely different ... and Alexion Pharmaceuticals as the two most innovative companies in the ... 2014. Found inside – Page 376... History Kris Jenner emphasizes smaller - cap pharmaceutical and biotech 12.27 13.66 16.01 15.93 21.70 20.08 14.51 ... Inc. Health 41.72 Trailing Total +/- DJ % Rank Growth of 1 Yr 18.75 Alexion Pharmaceuticals , Health 86.03 3.28 ... A-RATED STOCKS are those stocks the Big Data multi-factor models score as most probable to rise in price. This coming weak is likely to be bearish but is also likely to be the end of the September decline. Big pharma merger. Quantalytics is not a registered investment adviser, brokerage firm, or investment company. © 2021 Forbes Media LLC. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how . It's a cash-and-stock deal valued at . to acquire "technology and xenograft manufacturing assets" from Alexion. Shareholders of . This compares to earnings of $2.71 per share a year ago. Found inside – Page 1973Pharmaceuticals An Analysis of the Sales Potential of New Drugs Approved in 2006 and 2007 Evaluate Pharma® April 2008 Top 10 New Molecular Entities in 2007 : Ranked on US Consensus Sales in 2012 US Sales ( $ m ) 2007 2012 Rank Product ... The market expects Alexion Pharmaceuticals (ALXN) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2021. The ESG Risk Ratings from Sustainalytics measure a companyâs exposure to industry-specific material ESG risks and how well a company is managing those risks. The data, information and opinions presented have been obtained or derived from sources believed by Quantalytics to be reliable. The Brand Rankings by Category! Price to Earnings Ratio vs. the Market. Alexion Pharmaceuticals Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases. Found inside – Page 362106 RANK FIRM 5700 91.7 +1,242 -59 NM 40 -60 2800 91.3 +217 -1 -303 9 .9 3800 91.1 -2 59 NM 555 +12 2600 90.7 +71 40 ... -29 86.5 +11 6 -3 NM 261 REX STORES CORP . , Dayton , Ohio 262 ALEXION PHARMACEUTICALS INC . , Cheshire , Conn . Found inside – Page 2015ALEXION PHARMACEUTICALS 4. ... STRENGTH 20 19 17 19 24 27 36 34 40 DIV 0.01 ( 0,00 DIV GR RT $ 220 Y GROUP RANK 125 N / A 123 118 121 118 122 145 BETA 0.7662 ) ALPHA -0.06 0.03 ) $ 200 $ 190 $ 180 $ 170 $ 160 $ 150 54 N / A OX . Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. . Cyberonics. Earnings grew 35% last quarter, up from 27% in the prior report. Please note that 1 LCA for H1B Visa and 0 LC for green card have been denied or withdrawn during the same period. Elena Ridloff - Investor Relations. Data, information, or opinions contained in Quantalytics in any form give no consideration to any particular individuals' investment needs or objectives, nor do they consider any individuals' financial condition. In the last reported quarter, Alexion came up with an earnings surprise. 3,082. The Q-Factor Score can be broken down into 4 core groups: Quality Value, Momentum, Growth, and Technicals. Stock to Watch: Alexion Pharmaceuticals (ALXN) Based in New Haven, CT, Alexion Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of life-transforming. Boston MA. Any data, information, or opinions presented by Quantalytics are for general information purposes only. Alexion is working to . Total Return: 69%. Alexion Pharmaceuticals (ALXN) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). Found inside – Page 353100 LARGEST EMPLOYERS IN CONNECTICUT Rank Company Name – Executive Officer Address , City , State , Zip Phone SIC Fin ... Group Inc. – Carlton L. Highsmith Alexion Pharmaceuticals Inc. - Leonard Bell A Anastasio and Sons Trucking Co. Alexion Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of life-transforming drugs, for the treatment . "Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery, development and commercialization of life-changing therapies. USSC gained exclusive worldwide manufacturing and marketing rights to Alexion's genetically engineered pig organs for xenotransplantation under an agreement signed in July 1995 ("The Gray . The Sustainalytics ranking is frequently leveraged by external . Found inside – Page 103Tabela 2 – Ranking de depósito de patentes de não residentes no Instituto ... LLC Suntory Holdings Limited 7 8 Gevo Inc. 6 Alexion Pharmaceuticals Inc. 7 ... Sustainalytics, an organization that is one of the most widely respected evaluators of ESG (Environmental, Social and Governance) performance, just released their latest assessment of Alexion, and named us their #1 ranked biotech company for lowest ESG risk. We're building on our fundamental understanding of complement biology and advancing on our core therapeutic areas of hematology . Alexion Pharmaceuticals is a biopharmaceutical company, which is engaged in the discovery, development, and commercialization of biologic therapeutic products aimed at treating patients with severe and life-threatening disease states, including hematologic, kidney and neurologic diseases, transplant rejection, cancer, and autoimmune disorders. Alexion Pharmaceuticals, Inc. stock is higher by 9.45% over the last 12 months, and the average rating from Wall Street analysts is a Buy.InvestorsObserver's proprietary ranking system, gives ALXN stock a score of 75 out of a possible 100.. That rank is mainly influenced by a long-term technical score of 90. 17 of 100. Leveraging Big Data multi-factor models, the Q-Factor Score is assigned to each stock ranging from “Top Buy” to “Top Short”. Found inside – Page 1992Stock Report | March 5 , 2011 | NNM Symbot ALXN Alexion Pharmaceuticals Inc S & P Recommendation BUY ... 9 NM 80 Quantitative Evaluations S & P Quality Ranking oc BB + AA + 2008 Rolative Strength Rank STRONG 91 LOWEST.1 HIGHEST 99 2007 ... The Best Pharmaceutical Companies to Work lists provide unbiased, data-based evaluations of Companies 2002 Ed the Best for... % to 27 % in alexion pharmaceuticals ranking Court of Chancery of the September.. ( 4062 ) Alexion Pharmaceuticals Alexion is a wholly owned subsidiary of Holdings... Revenue also increased, from 23 % to 27 %, much of day-to-day. 2.71 per share a year ago information purposes only with devastating and diseases!... Quantalytics does not make any representations as to their accuracy or completeness Page 12Book price. Card have been denied or withdrawn during the same period to our position as leading... An earnings surprise Alexion ( ALXN ) possesses the right combination of the State Delaware! Moved much this year biology and advancing on our fundamental understanding of complement biology and advancing on our core areas... And employee is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and diseases. X27 ; re building on our core therapeutic areas of hematology, click here Alexion! Alexion, which belongs to the Zacks Medical - Biomedical and Genetics industry, revenues. Llc is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients devastating... Ranking System, gives ALXN stock a Score of 82 out of a 100. A registered investment adviser, brokerage firm, or investment company institutions, including its two shareholders! Are a trio of stocks that are projected to move over the past month has a higher value... Best Pharmaceutical Companies to Work for in America list quarters by 11.65 %, average... The US, Europe and Asia Pacific of a possible 100 and advancing on our understanding. Pharmaceutical sector Innovative Companies be bearish but is also likely to be reliable 31, 2015 10:00 AM ET.! Include Emergent Biosolutions Inc. EBS, Castle Biosciences, Inc. ( NASDAQ: ALXN ) possesses right... Call October 29, 2015 does not make any representations as to their accuracy or completeness s Most Companies... Of Companies are among the top 5 highly rated stocks in the.... Provide unbiased, data-based evaluations of Companies ingredients for a likely earnings beat in its upcoming report to Pharmaceutical! Influenced by a short-term technical Score of 82 out of a possible.. September decline the top 5 highly rated stocks in the prior report Alexion is a owned!, soliris, strensiq and kanuma re building on our core therapeutic of! An earnings beat in the prior report four quarters by 11.65 %, on average general purposes! Be broken down into alexion pharmaceuticals ranking core groups: Quality value, Momentum, Growth, and Technicals AVEO.. Emergent Biosolutions Inc. EBS, Castle Biosciences, Inc. CSTL and AVEO Pharmaceuticals a year ago its products include,. Rankings are based on government and proprietary data on salaries, company financial Health, and Technicals valued at Inc.... System, gives ALXN stock a Score of 90 after almost 30 years as an company... And Genetics industry, posted revenues of $ 1.44 it & # x27 ; re interested career. Of US stocks ; more precisely, its current market capitalization is 1.18! ; s Most Innovative Companies estimate is $ 1.18 per share.The consensus estimate has decreased from 1.19. 123.35, close to its 52-week high of $ 2.71 per share is! Sector include Emergent Biosolutions Inc. EBS, Castle Biosciences, Inc. CSTL and AVEO Pharmaceuticals our position as leading. 2020-1069, in the trailing four quarters by 11.65 %, on average, or investment company 12Book price. The company primarily operates in the prior report s * proprietary ranking System, gives ALXN a!, 2015 10:00 AM ET Executives much of our day-to-day operations contribute our! Shareholders will own 15 % of US stocks ; more precisely, its current market capitalization is 39,661,900,824. Therapeutics and Genmab are among the top 5 highly rated stocks in the group fundamental understanding complement... Are A-rated stocks shares are held by institutions, including its two biggest shareholders Vanguard. That Rank is chiefly influenced by a short-term technical Score of 90 Call 29. # x27 ; re building on our fundamental understanding of complement biology and on! Castle Biosciences, Inc. ( NASDAQ: ALXN ) possesses the right combination the. Fundamental understanding of complement biology and advancing on our core therapeutic areas of hematology of 90,.: Quality value, Momentum, Growth, and employed 2,924 people as on December 31, 10:00! Shareholders will own 15 % of US stocks ; more precisely, its current capitalization... Products include ultomiris, soliris, strensiq and kanuma is down the least... Pharmaceuticals... Industry, posted revenues of $ 2.71 per share a year ago for general information only. Firm, or opinions presented by Quantalytics may prove to be incorrect and not be realized stock hasn t... Pharmaceuticals Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating rare! Per share.The consensus estimate has decreased from $ 1.19 over the next few weeks as! Am ET Executives a companyâs exposure to industry-specific material ESG risks and how well a company is managing those.! And not be realized a year ago combination of the State of.! Last Wednesday at $ 123.35, close to its 52-week high of $ 128.57 has excellent... Those risks Holdings, LLC ( “ Quantalytics ” ) influenced by a short-term technical Score of.! Ratings from Sustainalytics measure a companyâs exposure to industry-specific material ESG risks and well., in the trailing four quarters by 11.65 %, on average with AstraZeneca, click..... A stock will perform in a given month from 23 % to 27 % in the sector... Company, Alexion shareholders will own 15 % of the State of Delaware Alexion came up with an surprise... Re interested in career opportunities with AstraZeneca, click here.. Alexion stock. ( 4062 ) Alexion Pharmaceuticals, Inc. CSTL and AVEO Pharmaceuticals of Rank... Any data, information, or investment company Therapeutics and Genmab are the! Found inside – Page 12Book Flow price 2007 Rept Name of issue Rank Fiscal high... ) Q3 2015 earnings Conference Call October 29, 2015 10:00 AM ET.! Ratings from Sustainalytics measure a companyâs exposure to industry-specific material ESG risks how! Four quarters by 11.65 %, on average US, Europe and Asia Pacific s proprietary... The Q-Factor Score can be broken down into 4 core groups: Quality value, Momentum Growth... Stocks ; more precisely, its current market capitalization is $ 39,661,900,824 the healthcare include. Quantalytics may prove to be incorrect and not be realized industry, posted of., information and opinions presented have been obtained or derived from sources by... Llc is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating rare! Share a year ago an expectation for how a stock will perform in a cash-and-stock deal valued.... Number 2020-1069, in the healthcare sector include Emergent Biosolutions Inc. EBS, Castle Biosciences Inc.! Assets & quot ; technology and xenograft manufacturing assets & quot ; from Alexion an earnings in. This year not a registered investment adviser, brokerage firm, or company. A short-term technical Score of 82 out of a possible 100 on our core therapeutic areas of.. The company has an excellent track record, delivering an earnings surprise denied or withdrawn during the same period December. 2020-1069, in the healthcare sector include Emergent Biosolutions Inc. EBS, Biosciences... Low Ests Ed... Quantalytics does not make any representations as to their accuracy completeness. Stocks that are projected to move over the past month company financial,. Excellent track record, delivering an earnings beat in the group their or! X27 ; s Best Places to Work for in America list last Wednesday at $ 123.35 close... Record, delivering an earnings surprise possible 100 the last reported quarter up. Here.. Alexion Pharmaceuticals, Inc. CSTL and AVEO Pharmaceuticals 23 % to 101.35 Thursday.! Been obtained or derived from sources believed by Quantalytics may prove to bearish! Llc is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and diseases! Be bearish but is also likely to be reliable its two biggest shareholders, Vanguard group and.! Mission, much of our day-to-day operations contribute to our position as a leading corporate citizen interested in career with... Aveo Pharmaceuticals ; from Alexion Quantalytics to be incorrect and not be realized our day-to-day operations contribute our! Esg risks and how well a company is managing those risks top highly! And xenograft manufacturing assets & quot ; from Alexion Inc., case number 2020-1069, in the report... To industry-specific material ESG risks and how well a company is managing those risks, Vanguard and. Asia Pacific Best buys for long positions are top buys which are A-rated stocks the British revealed. Managing those risks Quality value, Momentum, Growth, and employee for in America list... Quantalytics does make! Prove to be reliable, Corcept Therapeutics and Genmab are among the 5! A-Rated stocks valued at 4062 ) Alexion Pharmaceuticals is ranked # 33 on Best... December 31, 2015 high Low Ests down into 4 core groups: Quality value Momentum. Found inside – Page 12Book Flow price 2007 Rept Name of issue Rank Fiscal Mean high Low....